PER-018-04已完成未知
An open, randomized, international, multicenter, phase III study of Capecitabine (Xeloda®) in combination with cisplatin versus 5-FU / cisplatin in patients with advanced and / or metastatic gastric cancer.
PRODUCTOS ROCHE Q.F.S.A.,0 个研究点目标入组 0 人开始时间: 2004年5月3日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Adults 18 to 75 years of age
- •Advanced and/or metastatic gastric cancer with at least 1 measurable lesion
排除标准
- •Uncontrolled infection
- •Evidence of central nervous system (CNS) metastases
- •History of other malignancy within the last 5 years, except cured basal cell cancer of the skin or cured in-situ cancer of the uterine cervix
- •Radiation therapy or major surgery within 4 weeks of study drug
- •Previous chemotherapy
研究者
相似试验
进行中（未招募）
不适用
An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202EOsteogenesis ImperfectaEUCTR2004-001666-40-HUovartis Pharma AG130
进行中（未招募）
不适用
Bisphosphonate Treatment of Osteogenesis ImperfectaOsteogenesis ImperfectaEUCTR2015-003539-37-Outside-EU/EEAovartis158
进行中（未招募）
1 期
An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202EOsteogenesis ImperfectaEUCTR2004-001666-40-BEovartis Pharma AG130
进行中（未招募）
不适用
An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202EOsteogenesis ImperfectaEUCTR2004-001666-40-GBovartis Pharma AG130
进行中（未招募）
不适用
A Randomized, international, multi-center, open-label study to document pharmacokinetics and optimal timing of initiation of dronedarone TreatmEnt following long-term aMIodarone in patients with paroxysmal or perSistent Atrial Fibrillation whatever the reason for the change of treatment - ARTEMIS AF Long-TermParoxysmal or persistent atrial fibrillationMedDRA version: 14.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2010-019247-19-DKsanofi aventis groupe105